ParentPlus LLC was formed to alleviate male-factor subfertility by bringing biotechnology to millions of subfertile couples for whom intra-uterine insemination (IUI) might be an appropriate therapy. This therapy, with spousal or donor sperm, is underutilized perhaps in part because it frequently is neglected in the popular press. It is the company's belief that sperm from many subfertile men should be the target of a therapy based on modern biotechnology. Successful application of this concept could allow far more subfertile couples, when male-factor subfertility is a problem, to use IUI with spousal sperm to fulfill their dream of a having a baby. Hence, the focus of ParentPlus LLC is on reproductive media to enhance success primarily via IUI, but also enhancing IVF. In due course, demonstrated increased success rate with IUI using ParentPlus products will increase acceptance of IUI as the low cost alternative to highly publicized expensive treatments.
Missing: ParentPlus's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: ParentPlus's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
ParentPlus Frequently Asked Questions (FAQ)
Where is ParentPlus's headquarters?
ParentPlus's headquarters is located at 390 Yockey Road, Apollo.
What is ParentPlus's latest funding round?
ParentPlus's latest funding round is Unattributed VC.
How much did ParentPlus raise?
ParentPlus raised a total of $100K.
Who are the investors of ParentPlus?
Investors of ParentPlus include Pittsburgh Life Sciences Greenhouse.
Who are ParentPlus's competitors?
Competitors of ParentPlus include Lipella Pharmaceuticals, Longevica, GangaGen, Bloomage BioTech, ADV Bioscience and 11 more.
Compare ParentPlus to Competitors
Qwell Pharmaceuticals is a biotechnology company focused on small molecule development primarily for oncology indications.
Cizzle Biotechnology Ltd are a biotechnology company developing gene-based strategies for the treatment and diagnosis of lung cancer.nCizzle Biotechnology Ltd is a spin-out company from the University of York, established in 2005 with support from the Bioscience Yorkshire Enterprise Fellowship program and funding from Yorkshire Forward.
ADV Bioscience is a biotechnology service company engaged in the application of self-developed, public domain technologies and licensed technologies primarily for gene discovery research and validation. The company's focus is offering these technologies primarily to the Chinese market.
Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.
Martin-Protean is a biotechnology company that determines protein structure using chemical cross-linking and mass spectrometry. Its technology aims to provide insight into protein structure, facilitating drug design and discovery. Its products can be used by the pharmaceutical and biotechnology sectors as well as the NIH, national, and academic labs.
Solixia is a biotechnology company dedicated to helping cancer patients through the use of nanoparticle technology.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.